STRIDE

Trial Overview

Official Title

A Research Study to Compare a Medicine Called Semaglutide Against Placebo in People With Peripheral Arterial Disease and Type 2 Diabetes (STRIDE)

Study Purpose

This study is done to see if semaglutide has an effect on walking ability compared with placebo in people with peripheral arterial disease (PAD) and type 2 diabetes.

Diagnosis

Type 2 diabetes mellitus; symptomatic PAD with intermittent claudication

Eligibility

Exclusion Criteria:

Current or previous treatment with any GLP-1 receptor agonist (GLP-1-RA)
Walking ability limited by conditions other than PAD
Planned orthopaedic surgery in the legs, or other major surgery
Vascular revascularisation procedure of any kind 180 days prior to the day of screening.
Planned arterial revascularisation known on the day of screening.
Recent myocardial infarction, stroke, hospitalisation for unstable angina pectoris or transient ischemic attack
Heart failure presently classified as being in New York Heart Association (NYHA) class III-IV.

Intervention

Semaglutide vs placebo

For more information, visit the U.S. National Library of Medicine clinical trial database.

Key Participation Requirements

Gender

All

Age

19 and older

Enrollment Status

Recruiting

Phase

Phase III

Methodist Health System Trial Code

NCT04560998